European HealthTech | Nelson Advisors 3/3

The Paradigm Shift in MedTech M&A and Life Sciences Dealmaking: Licensing, Collaborative Governance and Risk Mitigated Capital Allocation

The global biopharmaceutical and medical technology (MedTech) sectors have entered a period of structural dealmaking transformation. Historically, large scale mergers and acquisitions (M&A) served as the primary instrument for multinational pharmaceutical corporations (MNCs) seeking to replenish depleted R&D pipelines, acquire proprietary drug discovery platforms and secure top-line growth. However, the economic rationale underpinning transformative M&A has been reshaped by a

Nelson Advisors

Aug 30

1 2

Add a title here. Make it bold and impactful. Click to edit.

Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV.